The next generation MOSkin dosimeter is the only medical radiation sensor technology in the world that accurately measures individual radiation doses and dose rates, in real time, at precisely defined and reproducible skin tissue and organ depth for the global $35 billion radiotherapy for cancer treatment, angiography equipment and CT and Xray scan markets. Electrogenics Laboratories Ltd (ELL), was formed in 2019 to commercialise this breakthrough, patented technology developed by the Centre for Medical Radiation Physics (CMRP), University of Wollongong (UOW), Australia. It has been fully tested and proven with over $8 million of grant funding in over 20 hospitals and clinics including Australia, Brazil, Italy, Malaysia and China. The ELL senior management and support staff team provide extensive experience in advanced technology product development and international business development to rapidly drive MOSkin to full global commercialisation and distribution. Distinguished Professor Anatoly Rozenfeld, Professor Michael Lerch, and Associate Professor Marco Petasecca from UOW are ELL’s scientific advisors. Point Blank Medical has been appointed exclusive Australian distributors. Transmedic Group has been exclusively appointed for the ASEAN and Hong Kong markets. Russian distribution is currently under negotiation. Australian development partners including Genesys Electronics Design, Design & Industry and Brandwood Biomedical will support the technical and regulatory requirements of the MOSkin technology for rapid commercialisation. ELL’s goal is to become the world leader in the development and provision of cutting edge, next generation radiation dosimetry solutions. The initial market sector is radiotherapy for cancer patients with an estimated market potential of US$950 million.